La chaîne d'options affiche les données clés des options sur actions de Monopar Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Monopar Therapeutics..

Monopar Therapeutics (NASDAQ:MNPR) Stock, Chaîne d'Options

MONOPAR THERAPEUTICS INC

Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics Inc

Health Care

Press Releases

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Earnings

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

General

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

News

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Financing

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

MNPR

Absci

Akebia Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

CytomX Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Gossamer Bio

Gyre Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Kodiak Sciences

Keros Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Myriad Genetics

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Regenxbio

Savara

Tyra Biosciences

UroGen Pharma

Verastem

Raymond James

Oppenheimer

HC Wainwright & Co.

Piper Sandler

BTIG

Comments

Monopar Therapeutics

Monopar Therapeutics (MNPR) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL